全站搜索
   
Abbott: Absorb is comparable to drug-eluting stents
Published:2009-12-15 16:22:19    Text Size:【BIG】【MEDIUM】【SMALL


Abbott Laboratories has launched its Absorbdrug-eluting bioresorbable vascular scaffold in Europe and parts of the Asia-Pacific region and Latin America.

While Absorb is similar to common vascular stents at first, restoring blood flow to a clogged vessel and administering the drug everolimus, it is made of polylactide, a common material in dissolving sutures, allowing it to be absorbed into the body after a few years, leaving behind a treated vessel free to move, flex, pulsate and dilate, according to the company which says it is thus safer and more effective than metallic stents. 

The commercial launch abroad follows five studies in more than 20 countries in which Absorb was found to perform just as well as best-in-class drug-eluting stents. 

“We are proud to be the first company to commercialize a drug eluting bioresorbable vascular scaffold, which has the potential to revolutionize the way physicians treat their patients with coronary artery disease," John Capek, Abbott's executive VP for devices, said in a statement.

Abbott is now moving at full speed to sell Absorb overseas, and, according to recent analysis, the company stands to rake in big profits in Europe. According to Millennium Research Group, the European market for vascular stents will drop 3.5 percent a year going forward, but dissolvable devices like Absorb are likely to grow in popularity.

Absorb is neither approved nor authorized for sale and currently is in development with no regulatory status in the United States. Absorb is authorized for sale in CE Mark countries and is now available in Europe, the Middle East, parts of Asia Pacific, including Hong Kong, Singapore, Malaysia and New Zealand, and parts of Latin America.
 
 
图片
Copyright(C)2015-2016 Duman Tech
脚注栏目